Cencora Inc
Cencora Inc를 보는 글로벌 시선
이 종목 직접 발언을 우선한 글로벌 증권사·투자대가의 공개 원문 · RICHMAP 추천 아님
재무 요약
Finnhub /stock/metric · 연간 기준 · 캐시 6h▸ Finnhub /stock/profile2 · 캐시 24h · 모든 수치 API 원값 (RICHMAP 가공·추정 없음)
관련 뉴스
Finnhub /company-news · 최근 14일 · 캐시 30minHere's Why You Should Retain Cencora Stock in Your Portfolio for Now
Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.
원문 보기 ↗ YahooAbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
원문 보기 ↗ YahooCencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue?
Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
원문 보기 ↗ YahooCencora Launches Cell and Gene Therapy Enablement for Health Systems
COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.
원문 보기 ↗ YahooIs Cencora (COR) Still Undervalued On Higher 2026 Guidance And Strong Q3 Earnings?
Cencora (COR) drew investor attention after third quarter results showed adjusted earnings per share of US$4.48, up 12% year over year, along with a higher fiscal 2026 adjusted earnings outlook. Cenco…
원문 보기 ↗ YahooWhat Cencora (COR)'s Cell and Gene Push and Higher 2026 Outlook Means For Shareholders
Cencora recently launched its Cell and Gene Therapy Enablement service through Accelerate Pharmacy Solutions to help health systems evaluate, build and scale advanced therapy programs, while also rais…
원문 보기 ↗ YahooJim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”
On the September 2 episode of Mad Money, Jim Cramer called Cardinal Health, Inc. (NYSE:CAH) one of his “absolute favorites” and mentioned its growing exposure to specialty pharmaceuticals and higher-m…
원문 보기 ↗ YahooCencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen
Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.
원문 보기 ↗ YahooIs Generics Still a Quiet Profit Engine for Cardinal Health?
Cardinal Health's generic volumes, profitable brand-to-generic conversions and Red Oak program continue to support Pharma profits.
원문 보기 ↗ YahooArtisan Sold Cencora (COR) as Earnings Momentum Slowed
Artisan Partners, an investment management company, released its second-quarter 2026 investor commentary for the “Artisan Global Opportunities Strategy”. The letter can be downloaded here. Global equi…
원문 보기 ↗ YahooCencora’s Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs
CONSHOHOCKEN, Pa., September 02, 2026--Cencora today launched a service to help health systems evaluate, build and scale cell and gene therapy (CGT) programs. Offered through Accelerate Pharmacy Solut…
원문 보기 ↗ YahooBeat the Market the Zacks Way: Accelerant, Insight, General Mills in Focus
Accelerant, Shopify and Carpenter Technology delivered strong gains, while Zacks upgrades and model portfolios spotlight key performers.
원문 보기 ↗ Yahoo내 성향 트레이더로 도전
주어는 당신의 성향이지 이 종목이 아닙니다. 6시간부터 1년까지 운용기간을 고르면, AI가 기간에 맞는 주기로 가상 매매합니다. 페이지를 닫아도 서버에서 계속 진행됩니다.
트레이더 성향 설정
객관식만 · 주관식 0 · 생성 후 변경 불가
본 페이지는 정보 제공 목적의 종목 정보 색인이며, 투자 권유·자문·중개가 아닙니다. RICHMAP은 증권사·금융투자업자가 아닙니다. 시세·재무·뉴스는 외부 데이터 소스(Finnhub 등)의 정보로 실시간성·정확성을 보증하지 않습니다. 모든 수치는 API 원값으로 RICHMAP의 가공·추정이 없으며, 조회 실패 시 "데이터 없음"으로 명시됩니다. 투자 판단과 그 결과 책임은 본인에게 있으며, 실제 거래는 정식 인가 증권사를 통해 본인 판단하에 진행하시기 바랍니다.